Fulgent Genetics price to sales ratio FLGT

Market value divided by revenue over the last twelve months, since 2017.

Today, Oct 23, 2026: 1.7×
10-year median: 2.9×
Against its 10-year history: 14th; percentile: 0 is its lowest day, 100 its highest
10-year range: 1.1× to 28.9×
Peer median: 6.9×

Fulgent Genetics' price to sales ratio is 1.7× as of Oct 23, 2026.

That is below its ten-year median of 2.9×, lower than on 86% of days in the last ten years.

Over that time it ranged from 1.1× in Jan 2023 to 28.9× in Feb 2021.

The median for 5 diagnostics and research stocks of a similar size is 6.9×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	1.7×	1.3×	2.8×
2025	2.6×	1.7×	2.9×
2024	2.0×	1.9×	2.9×
2023	3.0×	1.1×	3.8×
2022	1.1×	1.1×	2.3×
2021	2.9×	2.4×	28.9×
2020	9.4×	5.7×	24.0×
2019	8.3×	3.4×	9.9×
2018	3.1×	2.9×	4.9×
2017	3.8×	2.8×	10.8×

Against its peers

Companies in Medical - Diagnostics & Research nearest Fulgent Genetics' size, closest first, today.

Company	Price to sales ratio
FLGTFulgent Genetics	1.7×
NRCNRC Health	3.5×
ICCCImmucell	3.0×
CDNACareDx	7.8×
VCYTVeracyte	6.9×
BLLNBillionToOne	12.8×
Peer median	6.9×

Where Fulgent Genetics ranks

#13of 61Diagnostics and research stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Fulgent Genetics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.